

A2 antagonist. Selection of an antistress agent can be made according to broad criteria such as animal species, age, and types of stress. It is noted that antiprogestins are contradicted for use in pregnant or conceiving animals.--

Please incorporate the new Abstract of the Disclosure into the specification, submitted herewith on a separate sheet.

IN THE CLAIMS

Please cancel claims 1 through 51 and add new claims 52 through 92 per attached sheets.

CLAIMS:

Sub
R1
5 52. A composition comprising at least one therapeutic agent selected from the group consisting of anthelmintics, vitamins and amino acids, and at least one antistress agent.

10 53. A composition according to claim 52 wherein the antistress agent is selected from glucocorticoid inhibitors, corticotropin reducing hormone inhibitors, ACTH inhibitors, cholecystokinin inhibitors, benzodiazepines, gamma amino butyric acid potentiators, antiglutaminergics, and serotonergics.

15 54. A composition according to claim 52 wherein the antistress agent is selected from pyridyl propanones, antiprogestins, benzoylamino dipropylamino oxopentanoics, and amino acids or peptides that are corticotropin releasing factor (CRF) antagonists.

20 55. A composition according to claim 52 wherein the antistress agent is selected from metyrapone, mifepristone, proglumide, astressin, CRH 9-41, diazepam, allopregnanolone, dextromethorpon, zimelidine, and paroxetine.

25 56. A composition according to claim 55 wherein the antistress agent is selected from metyrapone, mifepristone, proglumide and astressin.

57. A composition according to claim 56 wherein the antistress agent is metyrapone.

30 58. A composition comprising at least one therapeutic agent selected from the group consisting of anthelmintics, vitamins and amino acids, and at least two antistress agents, independently selected from the agents according to claim 53.

59. A composition according to claim 58 wherein the two agents selected are metyrapone and mifepristone, metyrapone and proglumide, or metyrapone and astressin.

60. A composition according to claim 59 wherein the therapeutic agent is Vitamin C.

61. A composition according to claim 52 wherein the therapeutic agent further comprises one or more amino acids selected from valine, leucine and isoleucine.

62. A composition according to claim 61 wherein the therapeutic agent comprises
5 valine, leucine and isoleucine.

63. A composition according to claim 52 wherein the therapeutic agent is an anthelmintic.

10 64. A composition according to claim 63 which further comprises vitamin C.

65. A composition according to claim 63 which further comprises one or more amino acids selected from valine, leucine and isoleucine.

15 66. A composition according to claim 63 which further comprises valine, leucine and isoleucine.

67. A composition according to claim 52 wherein the, or each, antistress agent is present in an amount of from 0.0005 to 1 g/kg of liveweight.

20 68. A composition according to claim 67 wherein the, or each, antistress agent is present in an amount of from 0.001 to 0.1 g/kg.

25 69. A composition according to claim 67 wherein the, or each, antistress agent is present in an amount of 0.01 g/kg.

70. A composition according to claim 52 which further comprises a lipid membrane transfer facilitator.

30 71. A composition according to claim 70 wherein the facilitator is pyrrollopyrimidine.

72. A composition as claimed in claim 52 which further comprises a performance enhancer.

73. A composition according to claim 72 wherein the performance enhancer is an antibiotic.

74. A composition according to claim 73 wherein the antibiotic is avilamycin.

75. A composition according to claim 72 wherein the performance enhancer is an oligosaccharide.

76. A composition according to claim 75 wherein the oligosaccharide is Bio-Mos.

77. A composition according to claim 52 which is a slow release composition.

78. A composition according to claim 52 which further comprises a nitric oxide promoter.

79. A composition according to claim 78 wherein the promoter is selected from L-arginine diethylamine nitric oxide complex, sodium nitroprusside, and S-nitroso-N-acetylpenicillamine.

80. A composition according to claim 52 which further comprises at least one pharmaceutically or veterinarily acceptable diluent, excipient, carrier or solubiliser.

81. A method for promoting production gain in an animal, the method comprising administering to said animal at least one antistress agent selected from the agents according to claim 53,

82. A method for enhancing the efficacy of a therapeutic agent selected from the group consisting of anthelmintics, vitamins and amino acids, the method comprising the co-administration of at least one said therapeutic agent and at least one antistress agent to an animal.

83. A method for enhancing the efficacy of a therapeutic agent selected from the group consisting of anthelmintics, vitamins and amino acids, the method comprising the co-administration of at least one said therapeutic agent and at least one antistress agent to an animal wherein the antistress agent is selected from the agents according to claim 53.

84. A method for promoting production gain in an animal, the method comprising administering at least one therapeutic agent to the animal and reducing the stress experienced by the animal, wherein reduction in stress is achieved by administering at least one antistress agent according to claim 53.

5

85. A composition comprising a therapeutic agent and a nitric oxide promoter.

86. A composition according to claim 85 wherein the promoter is selected from S-nitroso-N-acetylpenicillamine, sodium nitroprusside and L-arginine diethylamine nitric oxide complex.

10

87. A composition according to claim 85 wherein the therapeutic agent is an anthelmintic.

15

88. A composition as claimed in claim 52 which is a drench.

89. A composition as claimed in claim 52 which is a pour-on formulation.

90. A composition as claimed in claim 52 which is formulated for injection.

20

91. A composition as claimed in claim 52 which is an animal feedstuff.

92. A composition as claimed in claim 52 which is in the form of a bolus.

25